Desprescripción: El desafío de transitar de la medicina basada en guías a la medicina centrada en la persona
DOI:
https://doi.org/10.61286/e-RPM.2026.372Palabras clave:
Desprescripción;Polifarmacia; Medicina centrada en la persona.Resumen
El ensayo analiza la desprescripción como el proceso sistemático para retirar medicamentos inapropiados, actuando como un puente esencial entre la medicina basada en guías y un modelo centrado en la persona. Aunque las guías clínicas optimizan resultados poblacionales, su aplicación rígida en adultos mayores con multimorbilidad suele derivar en polifarmacia iatrogénica. El texto identifica barreras como la inercia terapéutica y el temor del paciente, pero destaca facilitadores como la alfabetización en salud y el uso de herramientas como los criterios STOPP/START. Para una implementación exitosa, se propone un marco integrador en tres niveles: macro (políticas y métricas de calidad), meso (equipos multidisciplinarios y soporte tecnológico) y micro (toma de decisiones compartidas). En conclusión, más allá de la simple reducción de fármacos, la desprescripción estructurada se erige como una estrategia esencial que podría favorecer la autonomía y calidad de vida, honrando el principio de primum non nocere.
Citas
- 1. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Graham R, Mancher M, Miller Wolman D, et al., editors. Washington (DC): National Academies Press (US); 2011. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK209539/ https://doi.org/10.17226/13058
- 2. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34. https://doi.org/10.1001/jamainternmed.2015.0324
- 3. Linsky AM, Motala A, Booth M, Lawson E, Shekelle PG. Deprescribing in community-dwelling older adults: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(5):e259375. https://doi.org/10.1001/jamanetworkopen.2025.9375
- 4. Ballard T. Books: Chronic Disease Management: A New Paradigm For Care: GP Challenges. Br J Gen Pract. 2015;65(636):368. https://doi.org/10.3399/bjgp15X685849
- 5. Ie K, Aoshima S, Yabuki T, Albert SM. A narrative review of evidence to guide deprescribing among older adults. J Gen Fam Med. 2021;22(4):182-96. https://doi.org/10.1002/jgf2.464
- 6. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793-807. https://doi.org/10.1007/s40266-013-0106-8
- 7. Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G, et al. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. Health Technol Assess. 2022;26(32):1-148. https://doi.org/10.3310/AAFO2475
- 8. Turk A, Wong G, Mahtani KR, Maden M, Hill R, Ranson E, et al. Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review. BMC Med. 2022;20(1):297. https://doi.org/10.1186/s12916-022-02475-1
- 9. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716-24. https://doi.org/10.1001/jama.294.6.716
- 10. Bayliss EA, Gleason KS, Sheehan OC, Drace ML, Kraus C, Bedoy R, et al. Integrating patient education on deprescribing into care delivery: learnings from the Optimize pragmatic trial. Patient Educ Couns. 2026;142:109392. https://doi.org/10.1016/j.pec.2025.109392
- 11. Kaas Oldenburg LI, Dalin D, Drastrup AM, Vermehren C. Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing. Explor Res Clin Soc Pharm. 2022;5:100102. https://doi.org/10.1016/j.rcsop.2022.100102
- 12. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-81. https://doi.org/10.1111/jgs.18372
- 13. Kraut RY, Youngson E, Sadowski CA, et al. Antihypertensive deprescribing in frail long-term care residents (OptimizeBP): protocol for a prospective, randomised, open-label pragmatic trial. BMJ Open. 2024;14:e084619. https://doi.org/10.1136/bmjopen-2024-084619
- 14. Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):588-95. https://doi.org/10.1001/jamainternmed.2013.14764
- 15. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30(3):205-11. https://doi.org/10.1093/ageing/30.3.205
- 16. Muth C, van den Akker M, Blom JW, Mallen CD, Rochon J, Schellevis FG, et al. The Ariadne principles: how to handle multimorbidity in primary care consultations. BMC Med. 2014;12:223. https://doi.org/10.1186/s12916-014-0223-1
- 17. NHS England. Structured medication reviews and medicines optimisation [Internet]. London: NHS England; c2024 [cited 2026 Feb 02]. Available from: https://www.england.nhs.uk/primary-care/pharmacy/smr/
- 18. Drewelow E, Ritzke M, Altiner A, Icks A, Montalbo J, Kalitzkus V, et al. Development of a shared decision-making intervention to improve drug safety and to reduce polypharmacy in frail elderly patients living at home. PEC Innov. 2022;1:100032. https://doi.org/10.1016/j.pecinn.2022.100032
- 19. Li L, Greenfield G, Hayhoe BWJ, Lovett D, Novov V, Majeed A, et al. Structured medication reviews for patients with polypharmacy in primary care: a cross-sectional study in North West London, UK. JRSM Open. 2025;16(4):20542704251325056. https://doi.org/10.1177/20542704251325056
- 20. Isenor JE, Bai I, Cormier R, Helwig M, Reeve E, Whelan AM, et al. Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: a scoping review. Res Social Adm Pharm. 2021;17(7):1229-41. https://doi.org/10.1016/j.sapharm.2020.09.005
- 21. Lupi T, Esposito F, Romagnoli A. Statin deprescribing: a comprehensive review and development of a clinical algorithm for optimal patient management. Intern Med J. 2026;[Epub ahead of print]. https://doi.org/10.1111/imj.70341
- 22. Thompson W, Reeve E, Moriarty F, Maclure M, Turner J, Steinman MA, et al. Deprescribing: future directions for research. Res Social Adm Pharm. 2019;15(6):801-5. https://doi.org/10.1016/j.sapharm.2018.08.013
- 23. Heinrich CH, McHugh S, McCarthy S, Curran GM, Donovan MD. Multidisciplinary DEprescribing review for Frail oldER adults in long-term care (DEFERAL): implementation strategy design using behaviour science tools and stakeholder engagement. Res Social Adm Pharm. 2023;19(8):1202-13. https://doi.org/10.1016/j.sapharm.2023.05.002
- 24. Evrard P, Henrard S, Spinewine A. Development of a behavior-change intervention toward benzodiazepine deprescribing in older adults living in nursing homes. J Am Med Dir Assoc. 2024;25(8):105053. https://doi.org/10.1016/j.jamda.2024.105053
- 25. Pétein C, Chevallereau T, Aikpitanyi J, Evrard P, Tubeuf S, Henrard S, et al. Protocol to evaluate the feasibility of the D-PRESCRIBE intervention adapted to the Belgian community setting (END-IT CS study). BMJ Open. 2025;15(3):e085434. https://doi.org/10.1136/bmjopen-2024-085434
- 26. Evrard P, Damiaens A, Patey AM, Grimshaw JM, Spinewine A. Barriers and enablers towards benzodiazepine-receptor agonists deprescribing in nursing homes: a qualitative study of stakeholder groups. Explor Res Clin Soc Pharm. 2023;9:100258. https://doi.org/10.1016/j.rcsop.2023.100258
- 27. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889-98. https://doi.org/10.1001/jama.2018.16131
- 28. Ponce S, Galimany J, Fasce G, Arancibia S. Telegeriatría para el control de enfermedades crónicas mediante la reducción de la polifarmacia en la atención primaria de salud. Rev Panam Salud Publica. 2026;50:e8. https://doi.org/10.26633/RPSP.2026.8
- 29. Woodcock T, Lovett D, Ihenetu G, Novov V, Beaney T, Armani K, et al. Polypharmacy in primary care: a population-based retrospective cohort study of electronic health records. PLoS One. 2024;19(9):e0308624. https://doi.org/10.1371/journal.pone.0308624
- 30. Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galván-Santiago L, Serrano-Godoy M, Ribes-Murillo E, et al. Análisis poblacional de la prescripción potencialmente inadecuada en ancianos según criterios STOPP/START (estudio STARTREC). Aten Primaria. 2017;49(3):166-76. https://doi.org/10.1016/j.aprim.2016.02.013
- 31. Kraut R, Kamal O, Vucenovic A. Deprescribing antihypertensives with weekly taper intervals in long-term care, secondary data analysis of OptimizeBP data. Ann Fam Med. 2024;22(Suppl 1):6687. https://doi.org/10.1370/afm.22.s1.6687
- 32. Mangin D, Lamarche L, Agarwal G, Banh HL, Dore Brown N, Cassels A, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021;22(1):746. https://doi.org/10.1186/s13063-021-05685-9
- 33. Schleiden LJ, Klima G, Rodriguez KL, Ersek M, Robinson JE, Hickson RP, et al. Clinician and family caregiver perspectives on deprescribing chronic disease medications in older nursing home residents near the end of life. Drugs Aging. 2024;41(4):367-77. https://doi.org/10.1007/s40266-024-01110-3
- 34. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-623. https://doi.org/10.1111/bcp.12975
- 35. Gillon R. "Primum non nocere" and the principle of non-maleficence. Br Med J (Clin Res Ed). 1985;291(6488):130-1. https://doi.org/10.1136/bmj.291.6488.130
